Vericel Corp Ord

MediWound reported second quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, and reaffirmed full-year revenue guidance of $24 million to $26 million. The company said its EscharEx Phase III VLU trial is on track for interim sample size reassessment and enrollment completion by the end of the first quarter of 2027, and an updated U.S. market assessment now estimates annual peak sales of $1.05 billion for EscharEx across multiple chronic wound indications. For NexoBrid, Vericel reported its strongest quarter since launch with record revenue, hospital unit sales, and ordering centers, and MediWound entered a master service agreement with Vericel covering NexoBrid and next-generation product development. MediWound expects to begin recognizing revenue under the MSA in the second half of 2026, and it continues to advance a room temperature stable formulation of NexoBrid supported by $18.3 million in funding from the Department of War. The company reported a net loss of $7.4 million, or $0.57 per share, for the second quarter, compared with a net loss of $13.3 million, or $1.23 per share, in the prior year period.

The regenerative medicine market is projected to surpass US$100 billion within roughly a decade, driven by a shift from tissue replacement to regeneration using biomaterials, cell therapies, and 3D bioprinting. Independent estimates place the broad market in the tens of billions of dollars in 2026, with compound annual growth rates frequently estimated in the high teens to mid-20s percent. Key drivers include aging populations, the diabetes epidemic, rising surgical volumes, and growing demand in aesthetics, partly fueled by GLP-1 weight-loss medications. The sector spans profitable commercial leaders like Integra LifeSciences and Vericel to early-stage platform companies such as Conexeu Sciences, which began trading on Nasdaq in May 2026 with its collagen-based extracellular-matrix platform. Reimbursement policy and regulatory pathways remain critical risks, as illustrated by recent upheaval in the U.S. skin-substitute market affecting companies like Organogenesis and MiMedx.